GRM5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL155742	0.73	19/20
SCHEMBL102265	0.60	19/20
SCHEMBL138086	0.51	19/20
SCHEMBL155829	1.00	18/20
SCHEMBL155133	0.66	18/20
SCHEMBL103189	0.57	18/20
SCHEMBL136374	0.52	18/20
SCHEMBL155658	0.53	17/20
SCHEMBL136133	0.53	17/20
SCHEMBL101286	0.62	16/20
SCHEMBL134179	0.50	16/20
SCHEMBL72823	0.66	15/20
SCHEMBL83864	0.60	15/20
SCHEMBL84238	0.58	15/20
SCHEMBL136771	0.53	15/20
SCHEMBL136231	0.45	14/20
SCHEMBL84480	0.56	13/20
SCHEMBL31533	0.51	13/20
SCHEMBL102610	0.45	13/20
SCHEMBL103079	0.59	12/20

Clinical trials — most relevant to GRM5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine	PHASE4	COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation	PHASE3	COMPLETED
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
Evaluation of Schemes of Administration of Intravenous Ketamine in Depression	PHASE3	UNKNOWN
A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue	PHASE1/PHASE2	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
TRPM8 Activators for Peripheral Neuropathy	PHASE2	ACTIVE_NOT_RECRUITING
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain	PHASE1	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	PHASE1	RECRUITING
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial	PHASE1	COMPLETED
Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN	EARLY_PHASE1	COMPLETED
Changes in Glutamatergic Neurotransmission of Severe TBI Patients	EARLY_PHASE1	SUSPENDED
Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant	EARLY_PHASE1	RECRUITING
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Acamprosate: Genes Associated With Response	nan	COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
Sleep/Wake Cycle and Depression: An Imaging and Treatment Study	nan	COMPLETED
Examination of Glutamate and mGluR5 in Psychiatric Disorders	nan	COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
Neuroimmunology Registry and Biobank	nan	RECRUITING
Metabotropic Receptors For Glutamate Type 3 In Parkinson's	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GRM5 binder may also engage these)

Protein	Name	Similarity
Q3UVX5	—	1.000	Q3UVX5 →
P31424	—	1.000	P31424 →
GRM1	Metabotropic glutamate receptor 1	1.000	landscape →
P97772	—	1.000	P97772 →
P23385	—	1.000	P23385 →
Q5RAL3	—	1.000	Q5RAL3 →
GRM3	Metabotropic glutamate receptor 3	1.000	landscape →
Q1ZZH1	—	0.998	Q1ZZH1 →
Q09630	—	0.998	Q09630 →
Q9QYS2	—	0.997	Q9QYS2 →
P91685	—	0.997	P91685 →
G5ECB2	—	0.996	G5ECB2 →
H2L0Q3	—	0.992	H2L0Q3 →
P31422	—	0.991	P31422 →
Q80T41	—	0.991	Q80T41 →
P48442	—	0.991	P48442 →
Q9QY96	—	0.990	Q9QY96 →
CASR	Extracellular calcium-sensing receptor	0.990	landscape →
Q38PU2	—	0.990	Q38PU2 →
Q9Z2W8	—	0.989	Q9Z2W8 →
B3LZ39	—	0.989	B3LZ39 →
B4MU83	—	0.989	B4MU83 →
O70410	—	0.988	O70410 →
P35384	—	0.988	P35384 →
B4JHV0	—	0.988	B4JHV0 →
O62714	—	0.988	O62714 →
B1AS29	—	0.988	B1AS29 →
GRIA2	Glutamate receptor 2	0.988	landscape →
B4PVB0	—	0.987	B4PVB0 →
P42264	—	0.987	P42264 →